Scholar Rock Holding Corp (SRRK): who owns it and who trades it
As of Nov 16, 2026, SRRK insiders reported 37 open-market sales worth $19.4M and 6 purchases worth $12M in the last 12 months, with 41% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mo Qatanani (CHIEF SCIENTIFIC OFFICER), with $8.6M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Scholar Rock Holding
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SRRK
305 funds and institutions reported SRRK shares worth $7.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.7%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 18.00M | 15.66% | $990M | +4% |
| Siren, L.L.C. | 9.58M | 8.33% | $527M | -12% |
| BlackRock, Inc. | 9.49M | 8.26% | $522M | +27% |
| Samsara Biocapital, LLC | 6.90M | 6.00% | $379M | No change |
| T. Rowe Price Associates | 6.79M | 5.91% | $374M | +9% |
| Wellington Management Group LLP | 6.73M | 5.86% | $370M | +0% |
| Orbis Allan Gray Ltd | 5.93M | 5.16% | $326M | +42% |
| Vanguard Capital Management LLC | 4.77M | 4.15% | $262M | +23% |
| State Street Corp | 4.73M | 4.12% | $260M | +17% |
| Redmile Group, LLC | 4.31M | 3.75% | $237M | -52% |
| Norges Bank | 2.77M | 2.41% | $152M | – |
| Geode Capital Management, LLC | 2.75M | 2.40% | $151M | +28% |
| Massachusetts Financial Services Co | 2.61M | 2.27% | $143M | – |
| Bellevue Group AG | 2.45M | 2.13% | $135M | -32% |
| Jennison Associates LLC | 2.36M | 2.05% | $130M | -29% |
| Jupiter Topco LLC | 2.24M | 1.95% | $123M | – |
| Hood River Capital Management LLC | 2.22M | 1.94% | $122M | +9% |
| Driehaus Capital Management LLC | 2.21M | 1.92% | $121M | +15% |
| Eventide Asset Management, LLC | 2.11M | 1.84% | $116M | -4% |
| Polar Capital Holdings Plc | 1.88M | 1.64% | $103M | -5% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, SRRK insiders reported $12M of open-market purchases and $19.4M of sales. 41% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 26, 2026 | Srinivas Akkaraju | Director | Purchase | 48,988 | $41.59 | $2M | Form 4 |
| Oct 26, 2026 | Srinivas Akkaraju | Director | Purchase | 97,982 | $41.59 | $4.1M | Form 4 |
| Oct 23, 2026 | Srinivas Akkaraju | Director | Purchase | 47,000 | $41.31 | $1.9M | Form 4 |
| Oct 23, 2026 | Srinivas Akkaraju | Director | Purchase | 94,000 | $41.31 | $3.9M | Form 4 |
| Oct 23, 2026 | Srinivas Akkaraju | Director | Purchase | 500 | $41.82 | $20.9K | Form 4 |
| Oct 23, 2026 | Srinivas Akkaraju | Director | Purchase | 1,000 | $41.82 | $41.8K | Form 4 |
| Jul 1, 2026 | Jeffrey S. Flier | Director | Sale | 1,568 | $53.53 | $83.9K | Form 4 |
| Jul 1, 2026 | Jeffrey S. Flier | Director | Sale | 15 | $54.88 | $823 | Form 4 |
| Jul 1, 2026 | Jeffrey S. Flier | Director | Sale | 1,470 | $54.24 | $79.7K | Form 4 |
| Jul 1, 2026 | Michael Gilman | Director | Sale | 43 | $54.81 | $2.4K | Form 4 |
| Jul 1, 2026 | Michael Gilman | Director | Sale | 1,346 | $53.54 | $72.1K | Form 4 |
| Jul 1, 2026 | Michael Gilman | Director | Sale | 1,155 | $54.23 | $62.6K | Form 4 |
| Jul 1, 2026 | Kristina Burow | Director | Sale | 2,105 | $53.49 | $113K | Form 4 |
| Jul 1, 2026 | Kristina Burow | Director | Sale | 948 | $54.28 | $51.5K | Form 4 |
| Jul 1, 2026 | Joshua Reed | Director | Sale | 2,105 | $53.50 | $113K | Form 4 |
| Jul 1, 2026 | Katie Peng | Director | Sale | 2,988 | $53.56 | $160K | Form 4 |
| Jul 1, 2026 | Katie Peng | Director | Sale | 21 | $54.96 | $1.2K | Form 4 |
| Jul 1, 2026 | Katie Peng | Director | Sale | 2,437 | $54.25 | $132K | Form 4 |
| Apr 16, 2026 | Keith Woods | Chief Operating Officer | Sale | 10,220 | $49.57 | $507K | Form 4 |
| Apr 16, 2026 | Akshay Vaishnaw | President | Sale | 12,246 | $49.57 | $607K | Form 4 |
| Apr 16, 2026 | Vikas Sinha | CFO | Sale | 10,410 | $49.57 | $516K | Form 4 |
| Apr 16, 2026 | David Hallal | CEO | Sale | 30,615 | $49.57 | $1.5M | Form 4 |
| Feb 23, 2026 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sale plan | 7,427 | $46.94 | $349K | Form 4 |
| Feb 23, 2026 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sale plan | 200 | $48.48 | $9.7K | Form 4 |
| Feb 23, 2026 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sale plan | 857 | $47.86 | $41K | Form 4 |
| Feb 17, 2026 | Jing L. Marantz | CHIEF MEDICAL OFFICER | Sale | 4,157 | $46.53 | $193K | Form 4 |
| Feb 17, 2026 | Junlin Ho | GENERAL COUNSEL | Sale | 9,580 | $46.53 | $446K | Form 4 |
| Feb 17, 2026 | Caryn Parlavecchio | CHRO | Sale | 9,035 | $46.53 | $420K | Form 4 |
| Feb 17, 2026 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sale | 7,989 | $46.53 | $372K | Form 4 |
| Jan 22, 2026 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sale plan | 2,119 | $45.87 | $97.2K | Form 4 |
| Jan 22, 2026 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sale plan | 12,779 | $46.85 | $599K | Form 4 |
| Jan 16, 2026 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sale | 8,406 | $44.48 | $374K | Form 4 |
| Jan 16, 2026 | Caryn Parlavecchio | CHRO | Sale | 6,600 | $44.48 | $294K | Form 4 |
| Jan 16, 2026 | Jing L. Marantz | CHIEF MEDICAL OFFICER | Sale | 5,798 | $44.48 | $258K | Form 4 |
| Jan 16, 2026 | Junlin Ho | GENERAL COUNSEL | Sale | 8,016 | $44.48 | $357K | Form 4 |
| Jan 14, 2026 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sale plan | 13,112 | $45.20 | $593K | Form 4 |
| Jan 13, 2026 | Vikas Sinha | CFO | Sale | 16,755 | $42.70 | $715K | Form 4 |
| Jan 13, 2026 | Keith Woods | Chief Operating Officer | Sale | 16,746 | $42.70 | $715K | Form 4 |
| Jan 13, 2026 | Akshay Vaishnaw | President | Sale | 20,438 | $42.70 | $873K | Form 4 |
| Jan 13, 2026 | David Hallal | CEO | Sale | 57,450 | $42.70 | $2.5M | Form 4 |
| Dec 16, 2025 | Katie Peng | Director | Sale plan | 726 | $43.88 | $31.9K | Form 4 |
| Dec 16, 2025 | Katie Peng | Director | Sale plan | 280 | $44.63 | $12.5K | Form 4 |
| Dec 4, 2025 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sale plan | 136,462 | $45.21 | $6.2M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Srinivas Akkaraju | Director | $12M | – | Oct 26, 2026 |
| Mo Qatanani | CHIEF SCIENTIFIC OFFICER | – | $8.6M | Feb 23, 2026 |
| David Hallal | Chief Executive Officer, Director | – | $4M | Apr 16, 2026 |
| Akshay Vaishnaw | President of R&D, Director | – | $1.5M | Apr 16, 2026 |
| Vikas Sinha | Chief Financial Officer | – | $1.2M | Apr 16, 2026 |
| Keith Woods | Chief Operating Officer | – | $1.2M | Apr 16, 2026 |
| Junlin Ho | GENERAL COUNSEL | – | $802K | Feb 17, 2026 |
| Caryn Parlavecchio | CHRO | – | $714K | Feb 17, 2026 |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | – | $451K | Feb 17, 2026 |
| Katie Peng | Director | – | $338K | Jul 1, 2026 |
| Jeffrey S. Flier | Director | – | $164K | Jul 1, 2026 |
| Kristina Burow | Director | – | $164K | Jul 1, 2026 |
| Michael Gilman | Director | – | $137K | Jul 1, 2026 |
| Joshua Reed | Director | – | $113K | Jul 1, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SRRK short interest
High short interest. 19.3% of SRRK shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 50%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 23.48M SRRK shares were sold short, 19.3% of the shares outstanding, up 5.9% from the report before. At the average daily volume of 1.73M shares, buying them all back would take about 13.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 23.48M | 19.28% | +6% | 1.73M | 13.6 |
| Oct 15, 2026 | 22.18M | 18.21% | -2% | 1.74M | 12.7 |
| Sep 30, 2026 | 22.72M | 18.66% | +17% | 2.44M | 9.3 |
| Sep 15, 2026 | 19.41M | 15.94% | +8% | 1.79M | 10.8 |
| Aug 31, 2026 | 18.01M | 14.79% | -1% | 1.17M | 15.4 |
| Aug 14, 2026 | 18.22M | 14.96% | +3% | 919,253 | 19.8 |
| Jul 31, 2026 | 17.67M | 15.38% | +0% | 1.09M | 16.2 |
| Jul 15, 2026 | 17.60M | 15.32% | -4% | 1.09M | 16.1 |
| Jun 30, 2026 | 18.38M | 15.99% | +10% | 2.55M | 7.2 |
| Jun 15, 2026 | 16.73M | 14.56% | +2% | 1.04M | 16.2 |
| May 29, 2026 | 16.43M | 14.30% | +5% | 1.21M | 13.6 |
| May 15, 2026 | 15.66M | 13.63% | +5% | 1.31M | 11.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Scholar Rock Holding company events
Scholar Rock Holding filed 12 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 10, 2026.
- Nov 10, 2026AgreementScholar Rock Holding Corporation’s wholly owned subsidiary Scholar Rock Inc. entered into an asset purchase agreement with BioNTech US Inc. pursuant to which Scholar Rock agreed to sell a Rare Pediatric Disease Priority Review Voucher to Buyer. Filing
- Sep 15, 2026AnnouncementShared information with investors. Filing
- Sep 14, 2026AnnouncementThe Company announced that the FDA has approved ISEMBYLD™ (apitegromab-mstn) for the treatment of SMA in adults and children 2 years of age and older who are currently receiving a survival SMN2 targeted treatment. Filing
- Aug 6, 2026AnnouncementAs previously disclosed, Scholar Rock Holding Corporation entered into an Open Market Sale Agreement SM, dated November 14, 2022, with Jefferies LLC relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 5, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 31, 2026AnnouncementThe Company announced that it resubmitted its BLA to the FDA for apitegromab for the treatment of children and adults with SMA. The Company anticipates FDA acceptance within 30 days and a review period of up to six months from the date of resubmission, with a Prescription Drug User Fee Act action… Filing
- Mar 3, 2026ResultsAmended an earlier report. Released financial results. Filing
- Mar 3, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementThe Company will be conducting meetings with participants attending the 44th Annual J.P. Morgan Healthcare Conference during the week of January 12, 2026. Filing
- Dec 2, 2025AnnouncementAs previously disclosed, on October 10, 2025, Catalent Indiana, LLC (part of Novo Nordisk) informed Scholar Rock Holding Corporation that, following the Form FDA 483 issued to Catalent Indiana, LLC on July 14, 2025, the U.S. Food and Drug Administration determined that the inspection classification… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Scholar Rock Holding financials
Famous investors that hold SRRK
5 of the 50 well-known investors we track reported holding SRRK in their latest 13F filing. The largest position is Ken Griffin's, worth $101M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.09M | $101M | 0.1% | +531% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 437,363 | $21.1M | 0.0% | New |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 261,849 | $12.7M | 0.0% | -40% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 62,500 | $3M | 0.0% | -32% |
| Israel Englander · Millennium Management | Q3 2026 | 20,566 | $994K | 0.0% | +14% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named SRRK in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 4.8% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 4.8% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G/A | 7.2% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G/A | 7.2% |
Questions about Scholar Rock Holding Corp (SRRK) stock
Who owns the most SRRK stock?
The largest reported owner of Scholar Rock Holding Corp (SRRK) is FMR LLC (Fidelity), with 15.7% of the company. In total, 305 funds and institutions reported holding SRRK at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are SRRK insiders buying or selling?
In the last 12 months, SRRK insiders reported 6 open-market purchases worth $12M and 37 sales worth $19.4M. The latest trade was on Oct 26, 2026. See every trade.
What is the short interest in SRRK?
As of Oct 30, 2026, 23.48M SRRK shares were sold short, 19.3% of the shares outstanding, up 5.9% from the report before. At the average daily volume of 1.73M shares, buying them all back would take about 13.6 trading days (days to cover). See the history.
Which famous investors hold SRRK?
5 of the 50 well-known investors we track reported SRRK in their latest 13F filing, including Ken Griffin, Steve Cohen, Ken Fisher. The largest position is worth $101M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.